Vijay Kumar | Drug Discovery and Development | Editorial Board Member

Published on by Top Pharmaceutical

Assoc. Prof. Dr. Vijay Kumar | Drug Discovery and Development | Editorial Board Member

Dr B R Ambedkar NIT Jalandhar, India

Assoc. Prof. Dr. Vijay Kumar is a distinguished researcher, academician, and innovator in the fields of artificial intelligence, machine learning, biomedical informatics, cybersecurity, image processing, and computational intelligence. Over the course of his career, he has established himself as a prolific contributor whose research bridges advanced computational theories with real-world applications, particularly in healthcare, pandemic intelligence, medical imaging, network security, and autonomous systems. His academic journey is defined by a commitment to solving high-impact global challenges through intelligent algorithms, deep learning frameworks, optimization strategies, and secure data-driven technologies.Dr. Vijay Kumar’s scholarly work reflects exceptional depth and diversity. He has authored impactful publications in leading journals such as IEEE Transactions on Vehicular Technology, IEEE Journal of Biomedical and Health Informatics, Vaccine, Artificial Intelligence Review, Archives of Computational Methods in Engineering, Multimedia Tools and Applications, Computers in Biology and Medicine, and Biomedical Signal Processing and Control. His research spans a broad spectrum—from deepfake detection, autonomous vehicle visibility enhancement, multi-objective optimization, and cybersecurity frameworks, to intelligent diagnostic models for COVID-19, breast cancer, cervical cancer, and other critical diseases. His studies on advanced metaheuristic algorithms, chaotic encryption systems, drug synergy prediction, air-quality forecasting, and big healthcare data security have contributed significantly to modern computational science. A visionary in interdisciplinary AI, Dr. Kumar has collaborated extensively with international researchers, producing high-impact work on deep neural networks, generative adversarial models, hybrid optimization techniques, multimodal medical imaging, and cloud-based encryption systems. His contributions to pandemic preparedness, especially ML-driven vaccine development roadmaps and intelligent screening systems, highlight his dedication to translating technology into meaningful societal outcomes.He is also recognized for designing innovative algorithms such as lightweight NIDS architectures, evolutionary visibility restoration models, customized dehazing networks, and novel feature-selection optimizers. His body of work has become a reference point for emerging scholars in computer science, health informatics, and computational engineering.Dr. Vijay Kumar continues to lead transformative research, mentor young scientists, and contribute to global scientific advancement through his extensive publication record, collaborative projects, and commitment to innovation. His enduring academic excellence and forward-looking approach place him among the most influential researchers driving the future of intelligent systems and healthcare-focused artificial intelligence.

Profile: Google Scholar

Featured Publications

Katoch, S., Chauhan, S. S., & Kumar, V. (2020). A Review on Genetic Algorithm: Past, Present, and Future. Multimedia Tools and Applications, 52, 5252.

Dhiman, G., & Kumar, V. (2019). Seagull optimization algorithm: Theory and its applications for large‑scale industrial engineering problems. Knowledge‑Based Systems, 165, 169‑196.

Dhiman, G., & Kumar, V. (2017). Spotted Hyena Optimizer: A Novel Bio‑inspired based Metaheuristic Technique for Engineering Applications. Advances in Engineering Software, 114, 48‑70.

Dhiman, G., & Kumar, V. (2018). Emperor Penguin Optimizer: A Bio‑inspired Algorithm for Engineering Problems. Knowledge‑Based Systems, 159, 20‑50.

Singh, D., Kumar, V., Vaishali, & Kaur, M. (2020). Classification of COVID‑19 patients from chest CT images using multi‑objective differential evolution–based convolutional neural networks. European Journal of Clinical Microbiology & Infectious Diseases, 39, 1379‑1389.

Jaiswal, A., Gianchandani, N., Singh, D., Kumar, V., & Kaur, M. (2020). Classification of the COVID‑19 infected patients using DenseNet201 based deep transfer learning. Journal of Biomolecular Structure and Dynamics, 73, 1‑?.

Dhiman, G., Garg, M., Nagar, A., Kumar, V., & Dehghani, M. (2020). A Novel Algorithm for Global Optimization: Rat Swarm Optimizer. Journal of Ambient Intelligence and Humanized Computing, 5, 12‑?.

Das, N. N., Kumar, N., Kaur, M., Kumar, V., & Singh, D. (2020). Automated deep transfer learning‑based approach for detection of COVID‑19 infection in chest X‑rays. IRBM, 4, 25‑?.

Kaur, M., & Kumar, V. (2020). A comprehensive review on image encryption techniques. Archives of Computational Methods in Engineering, 27(1), 390.

Supraja R Prasad | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Ms. Supraja R Prasad | Drug Discovery and Development | Best Researcher Award

Kuvempu University | India

Ms. Supraja R. Prasad is a passionate researcher and educator specializing in organic synthesis, computational chemistry, and the design of biologically active heterocycles. Her academic and professional journey reflects a deep dedication to the integration of sustainable chemical methodologies with modern computational tools to advance the field of drug discovery. She is particularly recognized for her innovative work on the green synthesis of heterocyclic compounds, utilizing eco-friendly multicomponent reactions and natural catalysts to create molecular frameworks with promising therapeutic potential.Her research portfolio spans multiple interrelated areas, including mechanochemical synthesis of heterocyclic derivatives, density functional theory (DFT) studies, and spectral characterization of synthesized compounds. She has also explored the anti-diabetic activity of synthesized derivatives, focusing on developing safer and more efficient alpha-glucosidase inhibitors for managing type 2 diabetes mellitus. By combining experimental synthesis with computational modeling and molecular docking analyses, Ms. Prasad bridges the gap between theoretical chemistry and practical pharmacological applications.Her recent publication in the Journal of the Indian Chemical Society highlights her contributions to the synthesis and evaluation of alpha-glucosidase inhibitors, further strengthening her position within the scientific community. Through her work, she demonstrates how green chemistry can drive meaningful advancements in pharmaceutical sciences while minimizing environmental impact.Ms. Prasad’s academic mission is rooted in the belief that collaborative, interdisciplinary research can accelerate innovation. She emphasizes teamwork, creativity, and knowledge sharing as the cornerstones of impactful scientific progress. Her approach integrates sustainability, molecular insight, and therapeutic relevance — a combination that continues to shape her vision for future research.Her ongoing studies and contributions to organic synthesis, bioactivity assessment, and computational modeling position her as an emerging leader in sustainable chemistry and computational drug discovery, striving to make scientific research both environmentally responsible and socially beneficial.

Profile: Orcid

Featured Publications

Clay catalyzed dihydropyrimidinone synthesis: α-glucosidase inhibition and chemoinformatics. Journal of the Indian Chemical Society.

Matlou Mokgotho | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Prof. Dr. Matlou Mokgotho | Drug Discovery and Development | Best Researcher Award

Lecturer at Sefako Makgatho Health Science University | South Africa

Prof. Dr. Matlou Mokgotho is a distinguished biochemist and academic leader with over two decades of experience in higher education, research, and community development. Currently a Senior Lecturer at Tshwane University of Technology, he has previously served as Professor and Head of Department of Biochemistry at the University of Limpopo. His expertise spans molecular biology, proteomics, bioenergetics, enzymology, and mammalian cell cultures. Beyond academia, Dr. Mokgotho has actively contributed to community health awareness initiatives, youth leadership, and ethical oversight in research and professional bodies. His leadership, research excellence, and dedication to mentorship continue to inspire future scientists in South Africa.

Publication Profile 

Orcid

Education 

Prof. Dr. Matlou Mokgotho holds a Doctor of Philosophy in Biochemistry from the University of Limpopo, conferred. He earned his Master of Science in Biochemistry his Bachelor of Science Honours in Biochemistry  both from the University of the North. He also completed a Bachelor of Science in Biochemistry and Microbiology at the same institution. His academic foundation was laid at Seshigo High School, where he obtained his Senior Certificate. This strong educational background provided him with the knowledge and skills to excel in biochemical sciences and academic leadership.

Experience 

Prof. Dr. Matlou Mokgotho career spans roles from tutor to senior lecturer, professor, and department head. He began lecturing in Biochemistry at the University of the North before joining the University of Limpopo, where he advanced to Professor and Head of Department. His teaching portfolio covers biochemistry, molecular biology, proteomics, cell culture, and bioenergetics. He also served as CEO of Milestevens Development and Properties, showcasing leadership in management. Currently, he is Senior Lecturer at Tshwane University of Technology and a module critical reader at UNISA. His responsibilities include teaching, research coordination, and academic mentorship.

Awards and Honors 

Prof. Dr. Matlou Mokgotho has been recognized for his academic, community, and leadership contributions. He received certificates for AIDS Awareness campaigns and laboratory assistance during his early career, highlighting his dedication to education and health promotion. His leadership in youth and church organizations earned him certificates of moral leadership and community service, while his active role in HIV/AIDS awareness workshops reflected his commitment to social impact. As a council member of the South African Dental Technician Council, he contributed to professional ethics and governance. These accolades underscore his commitment to advancing science, leadership, and community development.

Research Focus 

Prof. Dr. Matlou Mokgotho research focuses on biochemistry, molecular biology, and proteomics, with a special interest in bioenergetics, protein structure-function relationships, and mammalian cell cultures. His work bridges fundamental and applied science, exploring enzymology, molecular mechanisms, and the applications of cell cultures in medical research. He has also contributed to developing experimental methodologies and training students in proposal writing, research principles, and dissertation development. His commitment to advancing biochemistry is reflected in his integration of teaching, research, and community engagement, with a strong emphasis on preparing students for careers in molecular science and addressing health challenges through biotechnological approaches.

Publication Top Notes

Gaetan Ligat | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Assoc. Prof. Dr. Gaetan Ligat | Drug Discovery and Development | Best Researcher Award

Assoc. Prof. Dr. Gaetan Ligat at Toulouse University | France

Assoc. Prof. Dr. Gaetan Ligat is a molecular virologist and principal investigator at Toulouse University, affiliated with INSERM UMR1291 and CNRS UMR5051. He leads the ViNeDys team at the Toulouse Institute for Infectious and Inflammatory Diseases, focusing on host–human cytomegalovirus interactions in brain tumors and therapeutic innovation. With extensive research and teaching experience across France, he has contributed to advancing antiviral strategies, mentoring young scientists, and promoting scientific communication. He is actively engaged in international collaborations, scientific societies, and community outreach, while securing multiple research grants to strengthen translational virology and oncology research.

Publication Profile 

Google Scholar

Education 

Assoc. Prof. Dr. Gaetan Ligat pursued his scientific training at Limoges University, France. He earned a Master of Science degree in Genetics and Physiology, which laid the foundation for his research career. He then advanced to doctoral studies at INSERM UMR1092, Limoges University, where he specialized in Molecular Virology, completing his PhD with distinction. His academic formation emphasized molecular biology, virus-host interactions, and translational virology, providing expertise in genetics, physiology, and applied biomedical sciences. This strong educational background enabled him to develop a career bridging fundamental research and therapeutic applications, particularly in virology, cancer biology, and innovative antiviral treatment strategies.

Experience 

Assoc. Prof. Dr. Gaetan Ligat is Associate Professor of Virology at Toulouse University, where he also serves as Principal Investigator and group leader of the ViNeDys team at the Infinity Institute. His work focuses on host–HCMV interactions and therapeutic innovation in brain tumors. Previously, he was a postdoctoral researcher at INSERM UMR1110 in Strasbourg, specializing in antiviral strategies. He began his research as a Master’s and PhD candidate at INSERM UMR1092, Limoges. Alongside research, he has coordinated training programs, practical courses, and supervised over 20 students. He is deeply involved in scientific societies, equality initiatives, and international collaborations.

Awards and Honors 

Assoc. Prof. Dr. Gaetan Ligat has received numerous prestigious recognitions, including the National Thesis Prize from the French Society of Microbiology and fellowships from the French National Agency for Research on AIDS and Viral Hepatitis (ANRS). He was awarded an ESCMID Research Grant, travel grants from the French Society of Microbiology, and registration bursaries for international congresses. His successful fundraising as principal investigator includes support from cancer foundations, patient associations, and Inserm/Regional PhD funding. These honors reflect both his scientific excellence and commitment to translational virology and oncology research. His awards highlight his impact on advancing antiviral and therapeutic research.

Research Focus 

Assoc. Prof. Dr. Gaetan Ligat research focuses on the molecular biology of human cytomegalovirus (HCMV) and its interaction with host cells, particularly in brain tumor environments. His work aims to understand how viral mechanisms contribute to disease progression and to identify novel therapeutic targets. He develops innovative antiviral strategies, including peptides and antibodies targeting HCMV protein interactions. His research also explores inflammatory responses, host-pathogen dynamics, and translational approaches for cancer treatment. Through collaborative projects and funded research programs, he seeks to bridge fundamental virology with therapeutic innovation, advancing the fight against viral infections and HCMV-related diseases in oncology.

Publication Top Notes

The human cytomegalovirus terminase complex as an antiviral target: a close-up view

Capsid assembly modulators as antiviral agents against HBV: molecular mechanisms and clinical perspectives

Hepatitis C virus (HCV)–apolipoprotein interactions and immune evasion and their impact on HCV vaccine design

Hepatitis B virus–host interactions and novel targets for viral cure

Hepatitis B virus core variants, liver fibrosis, and hepatocellular carcinoma

Targeting viral cccDNA for cure of chronic hepatitis B

The Yin and the Yang of extracellular vesicles during viral infections

Structures and divergent mechanisms in capsid maturation and stabilization following genome packaging of human cytomegalovirus and herpesviruses

Contrasting effect of new HCMV pUL54 mutations on antiviral drug susceptibility: benefits and limits of 3D analysis

Interferon‐Induced Transmembrane Proteins Mediate Viral Evasion in Acute and Chronic Hepatitis C Virus Infection

Identification of a short sequence in the HCMV terminase pUL56 essential for interaction with pUL89 subunit

Identification of amino acids essential for viral replication in the HCMV helicase-primase complex

Wai Har Ng | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Ms. Wai Har Ng | Drug Discovery and Development | Best Researcher Award

Senior Research Associate at National Cancer Centre Singapore | Singapore

Ms. Wai Har Ng is a Senior Research Associate at the National Cancer Centre Singapore with over two decades of experience in cancer biology and translational research. His scientific journey spans genetic engineering, molecular oncology, and personalized therapeutics, with a strong focus on hepatocellular carcinoma, peritoneal carcinomatosis, and colorectal cancer. A dynamic contributor to national research consortiums, Ng WH has authored numerous high-impact publications and excels in molecular, cellular, and in vivo experimental platforms. Known for his collaborative spirit, he plays a pivotal role in mentoring, protocol development, and driving clinical translation in cancer therapy through precision medicine and molecular marker discovery.

Publication Profile 

Scopus

Education

Ms. Wai Har Ng obtained a Master of Science in Genetic Engineering from University Putra Malaysia (2005), where his dissertation focused on gene expression profiling of oil palm root systems using EST and microarray technology. He earned his Bachelor of Science in Biotechnology (2000) from the same university, working on Arabidopsis root transformation. His foundational education was completed at Chong Hwa Independent High School, Kuala Lumpur, from 1990–2000, with certifications including STPM, SPM, and SRP. His early academic training at SRJK (C) Tsun Jin laid the groundwork for a career defined by scientific curiosity, discipline, and innovation in molecular biosciences.

Experience 

Ms. Wai Har Ng currently serves as a Senior Research Associate at the National Cancer Centre Singapore (2017–present), where he spearheads research on molecular therapeutics and biomarker discovery. He previously worked as a Research Officer and Research Associate at the same institute (2004–2017), contributing to groundbreaking oncology studies. Earlier, he served at the Malaysian Agricultural Research & Development Institute (MARDI) from 2003–2004. His academic skillset spans molecular biology, proteomics, imaging, animal studies, and lab management. Proficient in BSL2 safety, grant collaboration, and multidisciplinary research, he plays a key role in mentoring, lab operations, and translational biomedical research.

Awards 

While specific awards were not listed, Ng WH’s achievements are evident through his prolific publication record in high-impact journals, participation in national research consortia like the Singapore Peritoneal Oncology Study (SPOS) and Singapore Gastric Cancer Consortium (SGCC), and recognition as a core contributor to precision oncology research. His co-authorship on influential studies in Scientific Reports, Cell Reports Medicine, and International Journal of Molecular Sciences demonstrates academic recognition and leadership. His technical versatility and mentorship roles further highlight his contribution to national cancer research excellence. If formal awards were earned, these would further bolster his already commendable profile.

Research Focus 

Ng WH focuses on translational cancer research with emphasis on hepatocellular carcinoma, colorectal cancer, peritoneal carcinomatosis, and liposarcoma. His work integrates drug synergy, molecular profiling, biomarker discovery, and machine learning to optimize personalized cancer therapies. He is proficient in CRISPR, ddPCR, organoid modeling, xenografts, and immunofluorescence microscopy. A key area includes developing predictive molecular signatures for chemotherapy response and leveraging advanced imaging to study tumor behavior. With over 13 peer-reviewed publications, Ng WH bridges basic science and clinical application, contributing to a future where cancer treatment is personalized, precise, and highly effective.

Publication Top Notes

Title: Vinorelbine Improves the Efficacy of Sorafenib against Hepatocellular Carcinoma: A Promising Therapeutic Approach
Journal: International Journal of Molecular Sciences
Year: 2024
Citations: 5

Title: Everolimus Acts in Synergy with Vinorelbine to Suppress the Growth of Hepatocellular Carcinoma
Journal: International Journal of Molecular Sciences
Year: 2024
Citations: 4

Conclusion

Ms. Wai Har Ng is a highly competent and experienced researcher whose scientific contributions have advanced the field of cancer biology and therapeutics. Her technical mastery, consistent publication output, and collaborative involvement with national research consortia highlight her as a valuable asset to the research community. With increased visibility through leadership roles in publications and funding acquisition, she would stand out even more prominently. She is a strong and deserving candidate for the Best Researcher Award, given her sustained excellence, innovation, and impact in translational cancer research.